Donald C. Goff

Donald C. Goff's AcademicInfluence.com Rankings

Donald C. Goff

Biology

#8946

World Rank

#12092

Historical Rank

Neuroscience

#1284

World Rank

#1329

Historical Rank

biology Degrees

Download Badge

Biology

Donald C. Goff's Degrees

Doctorate Medicine Harvard University

Why Is Donald C. Goff Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Donald C. Goff's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III (2005) (1160)
Regionally localized thinning of the cerebral cortex in schizophrenia (2003) (929)
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. (2001) (896)
Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. (2000) (701)
Impaired recruitment of the hippocampus during conscious recollection in schizophrenia (1998) (592)
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. (1992) (583)
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline (2006) (544)
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls (2005) (518)
Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance (2000) (496)
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. (2005) (436)
Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia (2003) (431)
A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. (1999) (424)
Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI (1999) (405)
Reduced Sleep Spindles and Spindle Coherence in Schizophrenia: Mechanisms of Impaired Memory Consolidation? (2012) (385)
Cognitive therapy for psychosis in schizophrenia: an effect size analysis (2001) (362)
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. (2005) (357)
Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. (2005) (321)
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1 (2008) (288)
Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations (2002) (261)
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. (1995) (245)
Increased medial temporal lobe activation during the passive viewing of emotional and neutral facial expressions in schizophrenia (2006) (239)
The Effects of Transdermal Nicotine on Cognition in Nonsmokers with Schizophrenia and Nonpsychiatric Controls (2008) (233)
Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. (1998) (228)
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study (2008) (226)
Association of Psychiatric Disorders With Mortality Among Patients With COVID-19. (2021) (222)
Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. (2005) (211)
A Placebo-Controlled Pilot Study of the Ampakine CX516 Added to Clozapine in Schizophrenia (2001) (209)
The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome (2005) (207)
A Double-blind Placebo-Controlled Trial of Bupropion Sustained-Release for Smoking Cessation in Schizophrenia (2005) (197)
A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. (2001) (196)
Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. (2014) (187)
D-cycloserine added to clozapine for patients with schizophrenia. (1996) (185)
A 12-Week Double-Blind, Placebo-Controlled Study of Bupropion SR Added to High-Dose Dual Nicotine Replacement Therapy for Smoking Cessation or Reduction in Schizophrenia (2007) (184)
The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia (2015) (178)
Adverse Cardiac Effects Associated With Clozapine (2005) (177)
Test-retest reliability of a functional MRI working memory paradigm in normal and schizophrenic subjects. (2001) (174)
Placebo-controlled trial of glycine added to clozapine in schizophrenia. (2000) (173)
A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia (1999) (173)
Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. (1999) (170)
An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. (1998) (170)
The treatment of cognitive impairment in schizophrenia (2011) (166)
A Placebo-Controlled Add-On Trial of the Ampakine, CX516, for Cognitive Deficits in Schizophrenia (2008) (162)
Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia (2007) (155)
A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia (2011) (154)
Impaired hippocampal recruitment during normal modulation of memory performance in schizophrenia (2003) (148)
An Anterior-to-Posterior Shift in Midline Cortical Activity in Schizophrenia During Self-Reflection (2010) (147)
Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. (1996) (147)
Extinction Memory Is Impaired in Schizophrenia (2009) (147)
Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. (2004) (146)
Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles (2014) (141)
Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study (2008) (139)
Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages. (2010) (137)
Sustained activation of the hippocampus in response to fearful faces in schizophrenia (2005) (137)
Treatment of schizophrenia 1999 (1999) (136)
Folate, homocysteine, and negative symptoms in schizophrenia. (2004) (135)
Obsessive–compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status (2005) (134)
Dietary intake profile of patients with schizophrenia. (2006) (134)
The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. (2017) (132)
Reduced error-related activation in two anterior cingulate circuits is related to impaired performance in schizophrenia. (2008) (130)
Anterior and posterior hippocampal volumes in schizophrenia (2005) (127)
Self-reports of childhood abuse in chronically psychotic patients (1991) (127)
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. (2005) (127)
A pilot study of functional Cognitive Behavioral Therapy (fCBT) for schizophrenia (2005) (123)
A Single Dose of Nicotine Enhances Reward Responsiveness in Nonsmokers: Implications for Development of Dependence (2008) (122)
A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. (2009) (121)
Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia (2008) (118)
d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia (2002) (115)
Ionotropic glutamate receptors as therapeutic targets in schizophrenia. (2002) (115)
Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial (2007) (114)
Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. (2013) (113)
Lamotrigine as Add-On Therapy in Schizophrenia: Results of 2 Placebo-Controlled Trials (2007) (113)
An exploratory open‐label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia (2006) (113)
Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents (2003) (112)
Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia (2000) (112)
A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients (2005) (112)
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia (2012) (111)
Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. (2010) (111)
A failure of sleep-dependent procedural learning in chronic, medicated schizophrenia (2004) (111)
Increased temporal and prefrontal activity in response to semantic associations in schizophrenia. (2007) (110)
Dissociative Symptoms in Patients with Obsessive-Compulsive Disorder (1992) (109)
Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. (1991) (103)
Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients (2009) (102)
Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis. (2021) (98)
Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study (2009) (97)
Glutamate in schizophrenia: clinical and research implications (1997) (97)
Anterior cingulate cortex activation during cognitive interference in schizophrenia. (2004) (96)
Schizophrenic subjects show deficient inhibition but intact task switching on saccadic tasks (2002) (96)
Failure of neural responses to safety cues in schizophrenia. (2012) (96)
Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine (2002) (93)
Impaired hippocampal function during the detection of novel words in schizophrenia (2004) (93)
Contribution of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms to Negative Symptoms in Schizophrenia (2008) (93)
MTHFR 677C → T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val → Met (2008) (92)
An open trial of buspirone added to neuroleptics in schizophrenic patients. (1991) (91)
Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. (2007) (91)
Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. (1990) (91)
Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. (2004) (90)
The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized placebo-controlled trial. (2013) (90)
Do Baseline Client Characteristics Predict the Therapeutic Alliance in the Treatment of Schizophrenia? (2006) (88)
Motor cortical excitability in schizophrenia (2002) (87)
Neural evidence for faster and further automatic spreading activation in schizophrenic thought disorder. (2007) (84)
Reduced microstructural integrity of the white matter underlying anterior cingulate cortex is associated with increased saccadic latency in schizophrenia (2007) (83)
Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia (2010) (81)
The misattribution of salience in delusional patients with schizophrenia (2006) (81)
Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. (2009) (80)
A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia (1995) (78)
Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? (1986) (76)
Determining when impairment constitutes incapacity for informed consent in schizophrenia research. (2007) (76)
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1 (2008) (76)
Making sense of sentences in schizophrenia: electrophysiological evidence for abnormal interactions between semantic and syntactic processing. (2006) (75)
Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. (2013) (75)
Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment (2016) (75)
Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. (2015) (74)
Hippocampal and parahippocampal volumes in schizophrenia: a structural MRI study. (2006) (74)
Inflammation and schizophrenia (2007) (73)
High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia (2008) (70)
Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial (2005) (70)
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. (2006) (69)
d-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia (2011) (69)
The association between weight change and symptom reduction in the CATIE schizophrenia trial (2011) (69)
Folate supplementation in schizophrenia: A possible role for MTHFR genotype (2011) (68)
Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia (2007) (67)
Why all the confusion? Experimental task explains discrepant semantic priming effects in schizophrenia under “automatic” conditions: Evidence from Event-Related Potentials (2009) (66)
d-Cycloserine augmentation of cognitive remediation in schizophrenia (2014) (65)
A placebo-controlled study of sildenafil effects on cognition in schizophrenia (2008) (65)
The potential role of lamotrigine in schizophrenia (2005) (64)
Treatment of cardiac risk factors among patients with schizophrenia and diabetes. (2006) (64)
Risperidone-associated hyperprolactinemia. (2000) (64)
Efficacy of anticholinergic prophylaxis for neuroleptic-induced acute dystonia. (1988) (63)
Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week Open-Label Trial (2012) (62)
Negative Symptoms in Schizophrenia: Neurobiological Models and Treatment Response (1998) (62)
D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. (2012) (61)
Psychiatry and COVID-19. (2020) (61)
Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients. (2011) (61)
Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics (2005) (59)
Loneliness in schizophrenia and its possible correlates. An exploratory study (2016) (59)
Sexual functioning, psychopathology and quality of life in patients with schizophrenia (2007) (59)
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial (2016) (59)
Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia (2013) (59)
Initial medical work‐up of first‐episode psychosis: a conceptual review (2009) (58)
A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy (2015) (56)
Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia (2008) (56)
Erythromycin-induced clozapine toxic reaction. (1996) (55)
Drug interactions with antipsychotic agents. (1993) (55)
Metabolic effects of adjunctive aripiprazole in clozapine‐treated patients with schizophrenia (2013) (55)
Clinical characteristics, cognitive functioning, and criminal histories of outpatients with schizophrenia. (2003) (54)
Neuroimaging-genetic paradigms: a new approach to investigate the pathophysiology and treatment of cognitive deficits in schizophrenia. (2006) (54)
Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. (2005) (54)
Insight into current symptoms of schizophrenia. Association with frontal cortical function and affect (2004) (54)
Varenicline treatment for smokers with schizophrenia: a case series. (2008) (52)
Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia (2008) (52)
Functional Magnetic Resonance Imaging Reveals Neuroanatomical Dissociations During Semantic Integration in Schizophrenia (2008) (52)
Tardive dyskinesia and substrates of energy metabolism in CSF. (1995) (51)
Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of d-cycloserine (2005) (50)
Treatment‐Resistant Depression in the Elderly (1986) (50)
Schizophrenia patients show intact immediate error-related performance adjustments on an antisaccade task (2006) (49)
Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. (1998) (49)
Risperidone added to clozapine: impact on serum prolactin levels. (2001) (48)
The Delusion of Possession in Chronically Psychotic Patients (1991) (48)
Association of Hippocampal Atrophy With Duration of Untreated Psychosis and Molecular Biomarkers During Initial Antipsychotic Treatment of First-Episode Psychosis (2018) (47)
Intact suppression of increased false recognition in schizophrenia. (2002) (46)
Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR) (2010) (46)
Acanthosis nigricans in obese patients: Presentations and implications for prevention of atherosclerotic vascular disease. (2000) (45)
Predictors of early abstinence in smokers with schizophrenia. (2008) (45)
Building up linguistic context in schizophrenia: evidence from self-paced reading. (2006) (45)
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential (2015) (44)
Dysfunction of a cortical midline network during emotional appraisals in schizophrenia. (2011) (44)
Postpartum panic disorder. (1988) (43)
Fronto-Hippocampal Function During Temporal Context Monitoring in Schizophrenia (2006) (42)
Adjunctive Antidepressant Drug Therapies in the Treatment of Negative Symptoms of Schizophrenia (1996) (42)
Reduced functional connectivity in a right-hemisphere network for volitional ocular motor control in schizophrenia. (2010) (42)
Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. (2020) (41)
Striatal function in relation to negative symptoms in schizophrenia (2011) (39)
Drug development in schizophrenia: are glutamatergic targets still worth aiming at? (2015) (39)
Clozapine-associated reduction in arrest rates of psychotic patients with criminal histories. (2001) (39)
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia (2015) (39)
A double‐blind, placebo‐controlled trial of rosiglitazone for clozapine‐induced glucose metabolism impairment in patients with Schizophrenia (2009) (37)
Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. (2007) (37)
Disrupted Working Memory Circuitry in Schizophrenia: Disentangling fMRI Markers of Core Pathology vs Other Aspects of Impaired Performance (2016) (37)
Antisaccades and Task Switching (2002) (37)
Biomarkers for drug development in early psychosis: Current issues and promising directions (2016) (37)
Effects of D-Cycloserine Administration on Weekly Nonemotional Memory Tasks in Healthy Participants (2008) (37)
The effect of benztropine on haloperidol-induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double-blind trial. (1991) (36)
Biochemical, physiologic, and clinical effects of L-methylfolate in schizophrenia: A randomized controlled trial (2017) (36)
Lack of insula reactivity to aversive stimuli in schizophrenia (2013) (36)
Clinically Significant Interactions of Psychotropic Agents with Antipsychotic Drugs (1996) (35)
An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia (2013) (34)
Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia (1998) (34)
The relation between antisaccade errors, fixation stability and prosaccade errors in schizophrenia (2008) (34)
Colon perforation and peritonitis associated with clozapine. (2000) (33)
Clozapine for polydipsia and hyponatremia in chronic schizophrenics (1994) (33)
Training in a Clozapine Clinic for Psychiatry Residents: A Plea and Suggestions for Implementation (2013) (32)
Bitopertin: the good news and bad news. (2014) (32)
The Pharmacologic Treatment of Schizophrenia-2021. (2020) (32)
A placebo-controlled trial of selegiline (l-deprenyl) in the treatment of tardive dyskinesia (1993) (32)
Clozapine-induced sialorrhea treated with sublingual ipratropium spray: a case series. (2004) (32)
The evaluation and management of patients with first-episode schizophrenia: a selective, clinical review of diagnosis, treatment, and prognosis. (2007) (31)
Dissociation, childhood trauma, and the response to fluoxetine in bulimic patients. (1994) (29)
Dr. Goff Replies (1995) (29)
Distinguishing familiarity-based from source-based memory performance in patients with schizophrenia (2008) (28)
Integrating general health care in private community psychiatry practice. (2007) (28)
Reversed hemispheric asymmetry during simple visual perception in schizophrenia (2002) (28)
Abnormally persistent fMRI activation during antisaccades in schizophrenia: A neural correlate of perseveration? (2011) (28)
Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene (2019) (27)
Neurocognitive abnormalities during comprehension of real-world goal-directed behaviors in schizophrenia. (2009) (27)
Dissociable Genetic Contributions to Error Processing: A Multimodal Neuroimaging Study (2014) (26)
Treatment adherence in schizophrenia and schizoaffective disorder. (2011) (26)
What is perseverated in schizophrenia? Evidence of abnormal response plasticity in the saccadic system. (2005) (26)
Ziprasidone as an adjuvant for clozapine‐ or olanzapine‐associated medical morbidity in chronic schizophrenia (2009) (26)
Waist Circumference is the Best Anthropometric Predictor for Insulin Resistance in Nondiabetic Patients with Schizophrenia Treated with Clozapine but not Olanzapine (2009) (26)
Clinical Characteristics of Synthetic Cannabinoid Use in a Large Urban Psychiatric Emergency Setting (2017) (26)
A Hypomethylating Variant of MTHFR, 677C>T, Blunts the Neural Response to Errors in Patients with Schizophrenia and Healthy Individuals (2011) (26)
D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity (2016) (25)
The inter-trial effects of stimulus and saccadic direction on prosaccades and antisaccades, in controls and schizophrenia patients (2006) (25)
Bowel obsessions responsive to tricyclic antidepressants in four patients. (1987) (25)
Aberrant resting-state functional connectivity of salience network in first-episode schizophrenia (2020) (25)
Antisaccades and task switching: studies of control processes in saccadic function in normal subjects and schizophrenic patients. (2002) (24)
Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patients with schizophrenia on clozapine or risperidone. (2010) (24)
Anterior Hippocampal-Cortical Functional Connectivity Distinguishes Antipsychotic Naïve First-Episode Psychosis Patients From Controls and May Predict Response to Second-Generation Antipsychotic Treatment. (2020) (24)
Slow and steady: sustained effects of lexico-semantic associations can mediate referential impairments in schizophrenia (2011) (24)
Augmentation Strategies in the Treatment of Schizophrenia (2001) (23)
Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial. (1990) (23)
Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia (2013) (23)
THERAPEUTICS OF SCHIZOPHRENIA (2002) (22)
Homocysteine levels and glucose metabolism in non‐obese, non‐diabetic chronic schizophrenia (2006) (22)
MTHFR 677C>T effects on anterior cingulate structure and function during response monitoring in schizophrenia: a preliminary study (2011) (21)
Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers (2020) (21)
Selective emotional processing deficits to social vignettes in schizophrenia: an ERP study. (2011) (20)
Prospective memory performance in patients with drug-naïve, first-episode psychosis (2013) (20)
Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia (2011) (19)
The relationship of saccadic peak velocity to latency: evidence for a new prosaccadic abnormality in schizophrenia (2004) (19)
Antipsychotic polypharmacy: are two ever better than one? (2011) (19)
Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia. (2015) (18)
Aberrant Frontoparietal Function during Recognition Memory in Schizophrenia: A Multimodal Neuroimaging Investigation (2009) (18)
Task-switching in schizophrenia: active switching costs and passive carry-over effects in an antisaccade paradigm (2007) (18)
Association Between Antipsychotic Use and COVID-19 Mortality Among People With Serious Mental Illness. (2021) (18)
Partial resolution of ranitidine-associated delirium with physostigmine: case report. (1985) (17)
Efficacy and Tolerability of Adjunctive Intravenous Sodium Nitroprusside Treatment for Outpatients With Schizophrenia: A Randomized Clinical Trial. (2019) (17)
No Effect of Single-Dose Intranasal Insulin Treatment on Verbal Memory and Sustained Attention in Patients With Schizophrenia (2011) (17)
Higher fasting serum insulin levels are associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia (2006) (17)
Catatonic coma with profound bradycardia. (2007) (17)
Obsessive-compulsive disorder, depression, and the dexamethasone suppression test. (1987) (17)
The Genetics of Endophenotypes of Neurofunction to Understand Schizophrenia (GENUS) consortium: A collaborative cognitive and neuroimaging genetics project (2017) (17)
Focus on polypharmacy in schizophrenia: does anyone truly benefit? (2004) (17)
Review: lamotrigine may be an effective treatment for clozapine resistant schizophrenia (2009) (16)
High-Dose Oral Ziprasidone Versus Conventional Dosing in Schizophrenia Patients With Residual Symptoms: The ZEBRAS Study (2013) (16)
Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: A pilot study (2012) (16)
A placebo-controlled trial of trihexyphenidyl in unmedicated patients with schizophrenia. (1994) (16)
No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia (2013) (15)
Predicting relapse in schizophrenia: Is BDNF a plausible biological marker? (2017) (14)
Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State–wide Psychiatric Hospital System (2022) (14)
Diffusion kurtosis imaging of gray matter in schizophrenia (2019) (14)
Optical coherence tomography of the retina in schizophrenia: Inter-device agreement and relations with perceptual function (2020) (13)
Clinical practice guidelines: the Massachusetts experience in psychiatry. (1999) (13)
Both physical activity and food intake are associated with metabolic risks in patients with schizophrenia (2012) (13)
Neurocognitive mechanisms of conceptual processing in healthy adults and patients with schizophrenia. (2010) (13)
Has Multiple Personality Disorder Remained Consistent Over Time?: A Comparison of Past and Recent Cases (1993) (13)
No Effect of Adjunctive, Repeated-Dose Intranasal Insulin Treatment on Psychopathology and Cognition in Patients With Schizophrenia (2013) (13)
Higher Fasting Serum Insulin Is Associated with Increased Resting Energy Expenditure in Nondiabetic Schizophrenia Patients (2006) (13)
Sequence analysis of P21-activated kinase 3 (PAK3) in chronic schizophrenia with cognitive impairment (2008) (12)
The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia (2017) (12)
Intact hemispheric specialization for spatial and shape working memory in schizophrenia (2005) (12)
Association between catechol-O-methyltransferase genetic variation and functional connectivity in patients with first-episode schizophrenia (2018) (12)
The Psychologic Effects of Exercise (1985) (12)
Family-directed cognitive adaptation for schizophrenia. (2009) (12)
Depressive Symptoms in Schizophrenia Outpatients— Prevalence and Clinical Correlates (2008) (12)
Citalopram in first episode schizophrenia: The DECIFER trial (2019) (11)
Possession states: approaches to clinical evaluation and classification. (1992) (11)
A successful antipsychotic combination trial. Quo Vadis? (2004) (11)
The Therapeutic Role of d-Cycloserine in Schizophrenia. (2016) (10)
Brexpiprazole: A New Antipsychotic Following in the Footsteps of Aripiprazole. (2015) (10)
Polypharmacy in schizophrenia: a fuzzy concept. (2003) (10)
Cognitive Therapy for Delusions in Schizophrenia: Models, Benefits, and New Approaches (2004) (10)
Non‐Neurological Side‐Effects of Antipsychotic Drugs (2007) (10)
Glutamate Receptors in Schizophrenia and Antipsychotic Drugs (2000) (10)
Cognitive-Behavioral Treatment of Panic in Patients With Schizophrenia: Preliminary Findings (2000) (9)
Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study. (2016) (9)
Should CBT Target the Social Impairments Associated With Schizophrenia? (2004) (9)
Psychosis and Schizophrenia (2008) (8)
Anomalous Use of Context During Task Preparation in Schizophrenia: A Magnetoencephalography Study (2013) (8)
Pharmacologic Implications of Neurobiological Models of Schizophrenia (2005) (8)
Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophrenia (2021) (7)
Phenotypic characteristics in metabolically obese but normal weight non-diabetic patients with schizophrenia (2010) (7)
Maintenance treatment with long-acting injectable antipsychotics: comparing old with new. (2014) (7)
Promising Evidence of Antipsychotic Efficacy without Dopamine D2-Receptor Binding. (2020) (6)
Parietal memory network and default mode network in first‐episode drug‐naïve schizophrenia: Associations with auditory hallucination (2020) (6)
Quantitative Macromolecular Proton Fraction Mapping Reveals Altered Cortical Myelin Profile in Schizophrenia Spectrum Disorders (2021) (6)
Family-directed cognitive adaptation pilot: Teaching cognitive adaptation to families of individuals with schizophrenia (2016) (6)
MK-0777 FOR THE TREATMENT OF COGNITIVE IMPAIRMENTS IN PEOPLE WITH SCHIZOPHRENIA (2010) (5)
Relationship to Psychopathology and Medication Side Effects (1992) (5)
Two cases of hypomania following the addition of L-tryptophan to a monoamine oxidase inhibitor. (1985) (5)
A case of dramatic improvement of severe tardive dyskinesia after switch to aripiprazole. (2011) (4)
Clinical Efficacy and Target Engagement of Glutamatergic Drugs: Placebo-Controlled RCTs of Pomaglumetad and TS-134 for Reversal of Ketamine-Induced Psychotic Symptoms and PharmacoBOLD in Healthy Volunteers (2020) (4)
Have the Serotonin‐Dopamine Antagonists Rendered Traditional Antipsychotic Agents Obsolete? (1995) (4)
Effect of DAOA genetic variation on white matter alteration in corpus callosum in patients with first-episode schizophrenia (2020) (4)
Air pollution and hippocampal atrophy in first episode schizophrenia (2020) (4)
New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life. (2008) (4)
D-cycloserine augmentation of cognitive behavioral therapy for delusions: A randomized clinical trial (2020) (4)
A 23-year-old man with schizophrenia. (2002) (3)
Impairment in acquisition of conditioned fear in schizophrenia (2021) (3)
Effect of risperidone dose on serum prolactin level. (2001) (3)
Risperidone and Paliperidone (2009) (3)
Association of Aripiprazole With Reduced Hippocampal Atrophy During Maintenance Treatment of First-Episode Schizophrenia (2021) (3)
Functional imaging of memory retrieval differentiates deficit and nondeficit schizophrenia (1999) (3)
The stimulant challenge test in depression. (1986) (3)
Reduced Microstructural Lateralization in Males with Chronic Schizophrenia: A Diffusional Kurtosis Imaging Study. (2019) (3)
Dissociative Disorder, Psychosis, or Both? (1995) (3)
Effect of citalopram on hippocampal volume in first-episode schizophrenia: Structural MRI results from the DECIFER trial (2021) (3)
Glutamatergic Augmentation Strategies for Cognitive Impairment in Schizophrenia (1999) (3)
How addiction hijacks the brain. Desire initiates the process, but learning sustains it. (2011) (2)
Does Early Intervention Improve the Long-Term Course of Schizophrenia? (2020) (2)
The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures (2019) (2)
Decreased basal ganglia and thalamic iron in early psychotic spectrum disorders are associated with increased psychotic and schizotypal symptoms (2022) (2)
Antipsychotics and the Shrinking Brain (2011) (2)
What is the role of glutamate in schizophrenia? (1999) (2)
Merits of psychodynamic therapy (2010) (2)
Apparent decrease in schizophrenia (1991) (2)
Assessing Adherence to Antipsychotic Medications (2012) (2)
Is Pupillary Response a Biomarker for Effort and Defeatist Attitudes in Patients With Schizophrenia? (2016) (2)
Neural Correlates of the Preserved Inhibition of Return in Schizophrenia (2015) (2)
Should Sisyphus have taken melatonin? (2001) (2)
Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial (2019) (2)
Can Adjunctive Pharmacotherapy Reduce Hospitalization in Schizophrenia?: Insights From Administrative Databases. (2019) (1)
Family directed cognitive adaptation program for individuals with schizophrenia (2011) (1)
12 – Psychotic Patients (2010) (1)
Treatment of Psychotic Disorders (2011) (1)
Dr. Goff and Colleagues Reply (2005) (1)
Schizophrenics are not hypofrontal on a working memory task as measured by fMRI (1998) (1)
EFFECTS OF FOLIC ACID AND VITAMIN B12 SUPPLEMENTATION ON NEGATIVE SYMPTOMS AND RELATED MRI INDICES (2014) (1)
Maintenance TreatmentWith Varenicline for Smoking Cessation in PatientsWith Schizophrenia and Bipolar Disorder (2013) (1)
Chapter 14 – Psychotic Patients (2004) (1)
Rating Scales in Schizophrenia (2009) (1)
The Comorbidity of Obsessive-Compulsive Disorder and Schizophrenia (1999) (1)
Obsessive-compulsive symptoms among people with schizophrenia: Relation to psychotic symptoms, cognitive performance and antipsychotic medications (2003) (1)
SU93. Targeted Treatment of a Genetic Mutation in Glycine Decarboxylase With d-Cycloserine in Psychotic Disorders. (2017) (1)
Varenicline for Nicotine Dependence Treatment in Schizophrenia (2008) (1)
153. Abnormalities in thalamus and prefrontal cortex during episodic object recognition in schizophrenia (2000) (0)
Video game use among American teens Percentage (0)
ontribution of Methylenetetrahydrofolate Reductase MTHFR ) Polymorphisms to Negative Symptoms n Schizophrenia (2016) (0)
Changes in Cortical Myelination and Water Volume Fraction With Illness Duration in Schizophrenia (2020) (0)
Reply to Dr. Armstrong (1993) (0)
Polypharmacy in schizophrenia: A fuzzy concept. Author's reply (2003) (0)
Pathological gambling. Treatments are based on those used to treat addiction. (2010) (0)
Translational Neuroscience: Schizophrenia (2012) (0)
LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS IN SCHIZOPHRENIA: DO RECENT STUDIES CHANGE OUR UNDERSTANDING OF THEIR ROLE IN OUR TREATMENT ARMAMENTARIUM? (2012) (0)
La memoria de extinción está deteriorada en la esquizofrenia (2010) (0)
T179. Executive Function and Microstructural Lateralization Alterations in Schizophrenia (2019) (0)
Poster #35 PREFRONTAL CORTEX AND GOAL-DIRECTED BEHAVIOR IN SCHIZOPHRENIA: NEURAL MECHANISMS UNDERLYING INFLEXIBILITY (2012) (0)
Aberrant Resting-State Functional Connectivity of the Globus Pallidus Subregions in First-Episode Schizophrenia (2021) (0)
Alternative Beliefs Assessment (2012) (0)
The Social Brain, Stress, and Psychopathology (2016) (0)
Partial Pharmacological “Rescue” and MRS spectroscopy in Two Carriers of a Rare Marker Chromosome Containing Extra Copies of the GLDC Gene Encoding a Glycine-Degrading Enzyme Implicate NMDA Receptor Hypofunction in Psychosis (2020) (0)
Hippocampal Subfield Volumes Predict Disengagement from Maintenance Treatment in First Episode Schizophrenia (2022) (0)
Background Althoughpeoplewith schizophrenia display impaired abilities for consent, it is notknownhowmuch impairmentconstitutes incapacity. Aims To assess amethod for determiningthecategoricalcapacitystatus of potentialparticipants in schizophrenia research. Method Expert-judgement validation of cap (2007) (0)
Prefrontal cortex activation in schizophrenia is related to response accuracy on a working memory task as measured by fMRI (1997) (0)
Is anything consistent over time (1993) (0)
Metabolic side effects and risk of cardiovascular disease (2010) (0)
POSSIBILITIES AND IMPOSSIBILITIES OF TMS FOR THE TREATMENT OF HALLUCINATIONS (2012) (0)
117. Biomarker Assessment of Dose Dependent Target Engagement of mGluR-2,3 Partial Agonist for Schizophrenia Treatment (2019) (0)
Integrating general health care in private community psychiatry practice. (2007) (0)
Silent demons. (2008) (0)
Reply to Comments by Dr Babbar (2007) (0)
CONTRIBUTIONS OF THE COMT AND MTHFR GENES TO DEFICITS IN ADAPTIVE REAL-WORLD COMPREHENSION IN SCHIZOPHRENIA (2008) (0)
DIFFICULTIES WITH TRANSLATIONAL RESEARCH (2012) (0)
White Matter Microstructural Changes in Psychotic Spectrum Disorder are Associated With Cognitive Function and Symptoms (2021) (0)
SEARCHING FOR COGNITIVE ENHANCERS IN SCHIZOPHRENIA: THE TURNS PROGRAM STRATEGY (2010) (0)
Putamen Inflammation and its Association With Working Memory Impairments in Schizophrenia Spectrum Disorders (2020) (0)
P581. Inverse Relationships Between Basal Ganglia Iron and Positive Psychotic Symptoms in Early Psychotic Spectrum Disorders (2022) (0)
The significance of homocysteine levels in schizophrenia. Author's reply (2005) (0)
Treatment of Depression in Psychotic Disorders (2004) (0)
Adverse Effects of Psychotropic Drugs (1994) (0)
Optimizing the Pharmacologic Treatment of Individuals With First-Episode Psychosis. (2018) (0)
MULTIMODAL IMAGING STUDIES OF EARLY STAGES AND PERSISTENT SCHIZOPHRENIA (2010) (0)
MTHFR 677C [rightward arrow] T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val [rightward arrow] Met (2008) (0)
Chronic Mental Illness (2008) (0)
Dr. Goff and Associates Reply (2006) (0)
Neural correlates of recognition memory in schizophrenia (2003) (0)
P542. Perfusion and Diffusion Abnormalities in the Hippocampal Subfields in Psychotic Spectrum Disorders Associate With Memory Deficits (2022) (0)
P540. Psychotic Spectrum Disorder Depressive Subtype and Increased Perfusion in Temporal and Insular Regions (2022) (0)
Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial (2019) (0)
The Potential Role for D-cycloserine Facilitation of CBT in Schizophrenia (2011) (0)
T186. The Association Between Processing Speed and White Matter Tract Myelination in Schizophrenia (2019) (0)
Longitudinal study of inflammation and relapse in schizophrenia (2023) (0)
of L-Tryptophan to a Monoamine Oxidase Inhibitor (1985) (0)
Effect of Citalopram on Hippocampal Atrophy in First-Episode Psychosis: Structural MRI Results From the DECIFER Trial (2020) (0)
IVIM Modeling Shows Increased Perfusion and Free Water in Psychotic Spectrum Disorders Relate to Illness Duration and Cognitive Function (2021) (0)
ARIPIPRAZOLE IN COMBINATION WITH RISPERIDONE OR QUETIAPINE: RESULTS FROM A 16-WEEK, RANDOMIZED, DOUBLE-BLIND STUDY IN SUBJECTS WITH SCHIZOPHRENIA (2008) (0)
Association Between Gray Matter Microstructure, Cortical Thinning, Illness Duration and Executive Functioning in Psychotic Spectrum Disorders (2020) (0)
SELECTIVE NEURAL DEFICITS IN COMPREHENDING EMOTIONAL INFORMATION WITHIN SOCIAL VIGNETTES IN SCHIZOPHRENIA (2008) (0)
Microstructural and Microvascular Alterations in Psychotic Spectrum Disorders: A Three-Compartment Intravoxel Incoherent Imaging and Free Water Model. (2023) (0)
Selective anterior cingulate dysfunction during cognitive interference in schizophrenia (2003) (0)
Generalized anxiety disorder People who worry (0)
S171. EFFECT OF DAOA GENETIC VARIATION ON WHITE MATTER ALTERATION IN CORPUS CALLOSUM IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENIA (2020) (0)
Schizophrenia: Some Neglected Topics (2008) (0)
Increased Intracortical Myelin in Cognitively Preserved Patients With Psychotic Spectrum Disorders (2021) (0)
Water-suppressed proton nuclear magnetic resonance spectroscopy of plasma from schizophrenics and normal controls: A preliminary report (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Donald C. Goff?

Donald C. Goff is affiliated with the following schools:

Massachusetts General Hospital
New York University